SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-001081
Filing Date
2021-02-16
Accepted
2021-02-16 17:05:14
Documents
77
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20201231x10q.htm 10-Q 973814
2 EX-31.1 otlk-20201231ex311b56f0c.htm EX-31.1 9552
3 EX-31.2 otlk-20201231ex312c5be59.htm EX-31.2 6329
  Complete submission text file 0001558370-21-001081.txt   6061280

Data Files

Seq Description Document Type Size
4 EX-101.INS otlk-20201231.xml EX-101.INS 1344361
5 EX-101.SCH otlk-20201231.xsd EX-101.SCH 53767
6 EX-101.CAL otlk-20201231_cal.xml EX-101.CAL 53494
7 EX-101.DEF otlk-20201231_def.xml EX-101.DEF 237077
8 EX-101.LAB otlk-20201231_lab.xml EX-101.LAB 408033
9 EX-101.PRE otlk-20201231_pre.xml EX-101.PRE 413877
Mailing Address 4260 U.S. ROUTE 1 MONMOUTH JUNCTION NJ 08852
Business Address 4260 U.S. ROUTE 1 MONMOUTH JUNCTION NJ 08852 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 21640593
SIC: 2836 Biological Products, (No Diagnostic Substances)